Potential use of cannabimimetics in the treatment of cancer

  • Luciano De Petrocellis
  • Maurizio Bifulco
  • Alessia Ligresti
  • Vincenzo Di Marzo
Part of the Milestones in Drug Therapy MDT book series (MDT)


Transient Potential Receptor Vanilloid Type TRPV1 Receptor Prostaglandin Leukot Essent Fatty Acid Ajulemic Acid Uterine Cervix Cancer Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Mechoulam R (1986) The pharmacohistory of Cannabis sativa. In: R Mechoulam (ed.): Cannabis as therapeutic agents. CRC Press, Roca Raton, FL, 1–19Google Scholar
  2. 2.
    Williamson EM, Evans FJ (2000) Cannabinoids in clinical practice. Drugs 60: 1303–1314PubMedGoogle Scholar
  3. 3.
    Gaoni Y, Mechoulam R (1964) Isolation, structure, and partial synthesis of an active constituent of hashish. J Am Chem Soc 86: 1646–1647CrossRefGoogle Scholar
  4. 4.
    Walsh D, Nelson KA, Mahmoud FA (2003) Established and potential therapeutic applications of cannabinoids in oncology. Support Care Cancer 11: 137–143CrossRefPubMedGoogle Scholar
  5. 5.
    Pertwee RG (1997) Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 74: 129–180CrossRefPubMedGoogle Scholar
  6. 6.
    Di Marzo V (1998) ‘Endocannabinoids’ and other fatty acid derivatives with cannabimimetic properties: biochemistry and possble physiopathological relevance. Biochim Biophys Acta 1392: 153–175PubMedGoogle Scholar
  7. 7.
    McAllister SD, Glass M (2002) CB(1) and CB(2) receptor-mediated signalling: a focus on endocannabinoids. Prostaglandins Leukot Essent Fatty Acids 66: 161–171CrossRefPubMedGoogle Scholar
  8. 8.
    Paria BC, Das SK, Dey SK (1995) The preimplantation mouse embryo is a target for cannabinoid ligand-receptor signaling. Proc Natl Acad Sci USA 92: 9460–9464PubMedGoogle Scholar
  9. 9.
    Berrendero F, Sepe N, Ramos JA, Di Marzo V, Fernandez-Ruiz JJ (1999) Analysis of cannabinoid receptor binding and mRNA expression and endogenous cannabinoid contents in the developing rat brain during late gestation and early postnatal period. Synapse 33: 181–191CrossRefPubMedGoogle Scholar
  10. 10.
    Mechoulam R, Hanuš L (2002) Cannabidiol: an overview of some chemical and pharmacological aspects. Part I: chemical aspects. Chem Phys Lipids 121: 35–43CrossRefPubMedGoogle Scholar
  11. 11.
    Devane WA, Hanuš L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258: 1946–1949PubMedGoogle Scholar
  12. 12.
    Mechoulam R, Ben-Shabat S, Hanuš L, Ligumsky M, Kaminski NE, Schatz AR, Gopher A, Almog S, Martin BR, Compton DR et al. (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50: 83–90CrossRefPubMedGoogle Scholar
  13. 13.
    Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, Yamashita A, Waku K (1995) 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 215: 89–97CrossRefPubMedGoogle Scholar
  14. 14.
    Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346: 561–564CrossRefPubMedGoogle Scholar
  15. 15.
    Munro S, Thomas KL, Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365: 61–65CrossRefPubMedGoogle Scholar
  16. 16.
    Di Marzo V, Fontana A, Cadas H, Schinelli S, Cimino G, Schwartz JC, Piomelli D (1994) Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372: 686–691CrossRefPubMedGoogle Scholar
  17. 17.
    Bisogno T, Howell F, Williams G, Minassi A, Cascio MG, Ligresti A, Matias I, Schiano-Moriello A, Paul P, Williams EJ et al. (2003) Cloning of the first snl-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J Cell Biol 163: 463–468CrossRefPubMedGoogle Scholar
  18. 18.
    Hillard CJ, Edgemond WS, Jarrahian A, Campbell WB (1997) Accumulation of N-arachidonoylethanolamine (anandamide) into cerebellar granule cells occurs via facilitated diffusion. J Neurochem 69: 631–638PubMedGoogle Scholar
  19. 19.
    Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB (1996) Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384: 83–87CrossRefPubMedGoogle Scholar
  20. 20.
    Karlsson M, Contreras JA, Hellman U, Tornqvist H, Holm C (1997) cDNA cloning, tissue distribution, and identification of the catalytic triad of monoglyceride lipase. Evolutionary relationship to esterases, lysophospholipases, and haloperoxidases. J Biol Chem 272: 27218–27223CrossRefPubMedGoogle Scholar
  21. 21.
    Howlett AC (1995) Pharmacology of cannabinoid receptors. Annu Rev Pharmacol Toxicol 35: 607–634CrossRefPubMedGoogle Scholar
  22. 22.
    Piomelli D (2003) The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 4: 873–884CrossRefPubMedGoogle Scholar
  23. 23.
    Wilson RI, Nicoll RA (2002) Endocannabinoid signaling in the brain. Science 296: 678–682CrossRefPubMedGoogle Scholar
  24. 24.
    Guzman M, Sanchez C, Galve-Roperh I (2001) Control of the cell survival/death decision by cannabinoids. J Mol Med 78: 613–625CrossRefPubMedGoogle Scholar
  25. 25.
    Zhu LX, Sharma S, Stolina M, Gardner B, Roth MD, Tashkin DP, Dubinett SM (2000) Delta-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway. J Immunol 165: 373–380PubMedGoogle Scholar
  26. 26.
    Hart S, Fischer OM, Ullrich A (2004) Cannabinoids induce cancer cell proliferation via tumor necrosis factor alpha-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor. Cancer Res 64: 1943–1950PubMedGoogle Scholar
  27. 27.
    Sanchez MG, Sanchez AM, Ruiz-Llorente L, Diaz-Laviada I (2003) Enhancement of androgen receptor expression induced by R-methanandamide in prostate LNCaP cells. FEBS Lett 555: 561–566CrossRefPubMedGoogle Scholar
  28. 28.
    Munson AE, Harris LS, Friedman MA, Dewey WL, Carchman RA (1975) Antineoplastic activity of cannabinoids. JNatl Cancer Inst 55: 597–602Google Scholar
  29. 29.
    (1996) Toxicology and carcinogenesis studies of 1-trans-delta-9-tetrahydrocannabinol in F344N/N rats and BC63F1 mice. National Institutes of Health National Toxicology Program, NIH Publication No. 97-3362Google Scholar
  30. 30.
    De Petrocellis L, Melck D, Palmisano A, Bisogno T, Laezza C, Bifulco M, Di Marzo V (1998) The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc Natl Acad Sci USA 95: 8375–8380CrossRefPubMedGoogle Scholar
  31. 31.
    Melck D, Rueda D, Galve-Roperh I, De Petrocellis L, Guzman M, Di Marzo V (1999) Involvement of the cAMP/protein kinase A pathway and of mitogen-activated protein kinase in the anti-proliferative effects of anandamide in human breast cancer cells. FEBS Lett 463: 235–240CrossRefPubMedGoogle Scholar
  32. 32.
    Melck D, De Petrocellis L, Orlando P, Bisogno T, Laezza C, Bifulco M, Di Marzo V (2000) Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology 141: 118–126CrossRefPubMedGoogle Scholar
  33. 33.
    Bifulco M, Laezza C, Portella G, Vitale M, Orlando P, De Petrocellis L, Di Marzo V (2001) Control by the endogenous cannabinoid system of ras oncogene-dependent tumor growth. FASEB J 15: 2745–2747PubMedGoogle Scholar
  34. 34.
    Rueda D, Navarro B, Martinez-Serrano A, Guzman M, Galve-Roperh I (2002) The endocannabinoid anandamide inhibits neuronal progenitor cell differentiation through attenuation of the Rap1/B-Raf/ERK pathway. J Biol Chem 277: 46645–46650CrossRefPubMedGoogle Scholar
  35. 35.
    Casanova ML, Blazquez C, Martinez-Palacio J, Villanueva C, Fernandez-Acenero MJ, Huffman JW, Jorcano JL, Guzman M (2003) Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J Clin Invest 111: 43–50CrossRefPubMedGoogle Scholar
  36. 36.
    Mimeault M, Pommery N, Wattez N, Bailly C, Henichart JP (2003) Anti-proliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: implication of epidermal growth factor receptor down-regulation and ceramide production. Prostate 56: 1–12CrossRefPubMedGoogle Scholar
  37. 37.
    Portella G, Laezza C, Laccetti P, De Petrocellis L, Di Marzo V, Bifulco M (2003) Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis. FASEB J 17: 1771–1773PubMedGoogle Scholar
  38. 38.
    Sanchez C, de Ceballos ML, del Pulgar TG, Rueda D, Corbacho C, Velasco G, Galve-Roperh I, Huffman JW, Ramon y Cajal S, Guzman M (2001) Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. Cancer Res 61: 5784–5789PubMedGoogle Scholar
  39. 39.
    McKallip RJ, Lombard C, Fisher M, Martin BR, Ryu S, Grant S, Nagarkatti PS, Nagarkatti M (2002) Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood 100: 627–634CrossRefPubMedGoogle Scholar
  40. 40.
    Sanchez C, Galve-Roperh I, Canova C, Brachet P, Guzman M (1998) Delta9-tetrahydrocannabinol induces apoptosis in C6 glioma cells. FEBS Lett 436: 6–10CrossRefPubMedGoogle Scholar
  41. 41.
    Ruiz L., Miguel A, Diaz-Laviada I (1999) Delta9-tetrahydrocannabinol induces apoptosis in human prostate PC-3 cells via a receptor-independent mechanism. FEBS Lett 458: 400–404CrossRefPubMedGoogle Scholar
  42. 42.
    Galve-Roperh I, Sanchez C, Cortes ML, del Pulgar TG, Izquierdo M, Guzman M (2000) Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat Med 6: 313–319CrossRefPubMedGoogle Scholar
  43. 43.
    Gomez del Pulgar T, Velasco G, Sanchez C, Haro A, Guzman M (2002) De novo-synthesized ceramide is involved in cannabinoid-induced apoptosis. Biochem J 363: 183–188CrossRefPubMedGoogle Scholar
  44. 44.
    Ramer R, Weinzierl U, Schwind B, Brune K, Hinz B (2003) Ceramide is involved in r(+)-methanandamide-induced cyclooxygenase-2 expression in human neuroglioma cells. Mol Pharmacol 64: 1189–1198CrossRefPubMedGoogle Scholar
  45. 45.
    Guzman M (2003) Cannabinoids: potential anticancer agents. Nat Rev Cancer 3: 745–755CrossRefPubMedGoogle Scholar
  46. 46.
    Sarker KP, Obara S, Nakata M, Kitajima I, Maruyama I (2000) Anandamide induces apoptosis of PC-12 cells: involvement of superoxide and caspase-3. FEBS Lett 472: 39–44CrossRefPubMedGoogle Scholar
  47. 47.
    Sarker KP, Biswas KK, Rosales JL, Yamaji K, Hashiguchi T, Lee KY, Maruyama I (2003) Ebselen inhibits NO-induced apoptosis of differentiated PC12 cells via inhibition of ASK1-p38 MAPK-p53 and JNK signaling and activation of p44/42 MAPK and Bcl-2. J Neurochem 87: 1345–1353PubMedGoogle Scholar
  48. 48.
    Rak J, Mitsuhashi Y, Sheehan C, Tamir A, Viloria-Petit A, Filmus J, Mansour SJ, Ahn NG, Kerbel RS (2000) Oncogenes and tumor angiogenesis: differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts. Cancer Res 60: 490–498PubMedGoogle Scholar
  49. 49.
    Hetian L, Ping A, Shumei S, Xiaoying L, Luowen H, Jian W, Lin M, Meisheng L, Junshan Y, Chengchao S (2002) A novel peptide isolated from a phage display library inhibits tumor growth and metastasis by blocking the binding of vascular endothelial growth factor to its kinase domain receptor. J Biol Chem 277: 43137–43142CrossRefPubMedGoogle Scholar
  50. 50.
    Casanova ML, Larcher F, Casanova B, Murillas R, Fernandez-Acenero MJ, Villanueva C, Martinez-Palacio J, Ullrich A, Conti CJ, Jorcano JL (2002) A critical role for ras-mediated, epidermal growth factor receptor-dependent angiogenesis in mouse skin carcinogenesis. Cancer Res 62: 3402–3407PubMedGoogle Scholar
  51. 51.
    Blazquez C, Casanova ML, Planas A, Del Pulgar TG, Villanueva C, Fernandez-Acenero MJ, Aragones J, Huffman JW, Jorcano JL, Guzman M (2003) Inhibition of tumor angiogenesis by cannabinoids. FASEB J 17: 529–531PubMedGoogle Scholar
  52. 52.
    Joseph J, Niggemann B, Zaenker KS, Entschladen F (2004) Anandamide is an endogenous inhibitor for the migration of tumor cells and T lymphocytes. Cancer Immunol Immunother 53: 723–728CrossRefPubMedGoogle Scholar
  53. 53.
    Pagotto U, Marsicano G, Fezza F, Theodoropoulou M, Grubler Y, Stalla J, Arzberger T, Milone A, Losa M, Di Marzo V et al. (2001) Normal human pituitary gland and pituitary adenomas express cannabinoid receptor type 1 and synthesize endogenous cannabinoids: first evidence for a direct role of cannabinoids on hormone modulation at the human pituitary level. J Clin Endocrinol Metab 86: 2687–2696CrossRefPubMedGoogle Scholar
  54. 54.
    Maccarrone M, Attina M, Cartoni A, Bari M, Finazzi-Agrò (2001) A Gas chromatography-mass spectrometry analysis of endogenous cannabinoids in healthy and tumoral human brain and human cells in culture. J Neurochem 76: 594–601CrossRefPubMedGoogle Scholar
  55. 55.
    Schmid PC, Wold LE, Krebsbach RJ, Berdyshev EV, Schmid HH (2002) Anandamide and other N-acylethanolamines in human tumors. Lipids 37: 907–912PubMedGoogle Scholar
  56. 56.
    Maccarrone M (2004) Levels of N-acylethanolamines in human tumors: in search of reliable data. Lipids 39: 193–194PubMedGoogle Scholar
  57. 57.
    Ligresti A, Bisogno T, Matias I, De Petrocellis L, Cascio MG, Cosenza V, D’argenio G, Scaglione G, Bifulco M, Sorrentini I, Di Marzo V (2003) Possible endocannabinoid control of colorectal cancer growth. Gastroenterology 125: 677–687CrossRefPubMedGoogle Scholar
  58. 58.
    Bisogno T, Katayama K, Melck D, Ueda N, De Petrocellis L, Yamamoto S, Di Marzo V (1998) Biosynthesis and degradation of bioactive fatty acid amides in human breast cancer and rat pheochromocytoma cells-implications for cell proliferation and differentiation. Eur J Biochem 254: 634–642CrossRefPubMedGoogle Scholar
  59. 59.
    Di Marzo V, Melck D, Orlando P, Bisogno T, Zagoory O, Bifulco M, Vogel Z, De Petrocellis L (2001) Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. Biochem J 358: 249–255CrossRefPubMedGoogle Scholar
  60. 60.
    De Petrocellis L, Bisogno T, Ligresti A, Bifulco M, Melck D, Di Marzo V (2002) Effect on cancer cell proliferation of palmitoylethanolamide, a fatty acid amide interacting with both the cannabinoid and vanilloid signalling systems. Fundam Clin Pharmacol 16: 297–302CrossRefPubMedGoogle Scholar
  61. 61.
    Pertwee RG (2004) New pharmacological targets for cannabinoids. Curr Neuropharmacol 2: 9–29CrossRefGoogle Scholar
  62. 62.
    Maccarrone M, Lorenzon T, Bari M, Melino G, Finazzi-Agrò A (2000) Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for a protective role of cannabinoid receptors. J Biol Chem 275: 31938–31945CrossRefPubMedGoogle Scholar
  63. 63.
    Szallasi A, Blumberg PM (1999) Vanilloid (Capsaicin) receptors and mechanisms. Pharmacol Rev 51: 159–212PubMedGoogle Scholar
  64. 64.
    Di Marzo V, De Petrocellis L, Fezza F, Ligresti A, Bisogno T (2002) Anandamide receptors. Prostaglandins Leukot Essent Fatty Acids 66: 377–391CrossRefPubMedGoogle Scholar
  65. 65.
    Melck D, Bisogno T, De Petrocellis L, Chuang H, Julius D, Bifulco M, Di Marzo V (1999) Unsaturated long-chain N-acyl-vanillyl-amides (N-AVAMs): vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CB1 cannabinoid receptors. Biochem Biophys Res Commun 262: 275–284CrossRefPubMedGoogle Scholar
  66. 66.
    Contassot E, Tenan M, Schnuriger V, Pelte MF, Dietrich PY (2004) Arachidonyl ethanolamide induces apoptosis of uterine cervix cancer cells via aberrantly expressed vanilloid receptor-1. Gynecol Oncol 93: 182–188CrossRefPubMedGoogle Scholar
  67. 67.
    Jacobsson SO, Wallin T, Fowler CJ (2001) Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids. Relative involvement of cannabinoid and vanilloid receptors. J Pharmacol Exp Ther 299: 951–959PubMedGoogle Scholar
  68. 68.
    Grant ER, Dubin AE, Zhang SP, Zivin RA, Zhong Z (2002) Simultaneous intracellular calcium and sodium flux imaging in human vanilloid receptor 1 (VR1)-transfected human embryonic kidney cells: a method to resolve ionic dependence of VR1-mediated cell death. J Pharmacol Exp Ther 300: 9–17CrossRefPubMedGoogle Scholar
  69. 69.
    Biro T, Brodie C, Modarres S, Lewin NE, Acs P, Blumberg PM (1998) Specific vanilloid responses in C6 rat glioma cells. Brain Res Mol Brain Res 56: 89–98CrossRefPubMedGoogle Scholar
  70. 70.
    Macho A, Calzado MA, Munoz-Blanco J, Gomez-Diaz C, Gajate C, Mollinedo F, Navas P, Munoz E (1999) Selective induction of apoptosis by capsaicin in transformed cells: the role of reactive oxygen species and calcium. Cell Death Differ 6: 155–165CrossRefPubMedGoogle Scholar
  71. 71.
    Bisogno T, Hanuš L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, Schiano Moriello A, Davis JB, Mechoulam R, Di Marzo V (2001) Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 134: 845–852CrossRefPubMedGoogle Scholar
  72. 72.
    Jordt SE, Bautista DM, Chuang HH, McKemy DD, Zygmunt PM, Hogestatt ED, Meng ID, Julius D (2004) Mustard oils and cannabinoids excite sensory nerve fibres through the TRP channel ANKTM1. Nature 427: 260–265CrossRefPubMedGoogle Scholar
  73. 73.
    Carchman RA, Harris LS, Munson AE (1976) The inhibition of DNA synthesis by cannabinoids. Cancer Res 36: 95–100PubMedGoogle Scholar
  74. 74.
    Jacobsson SO, Rongard E, Stridh M, Tiger G, Fowler CJ (2000) Serum-dependent effects of tamoxifen and cannabinoids upon C6 glioma cell viability. Biochem Pharmacol 60: 1807–1813CrossRefPubMedGoogle Scholar
  75. 75.
    Mechoulam R, Hanuš L (2002) Cannabidiol: an overview of some chemical and pharmacological aspects. Part I: chemical aspects. Chem Phys Lipids 121: 35–43CrossRefPubMedGoogle Scholar
  76. 76.
    Massi P, Vaccani A, Ceruti S, Colombo A, Abbracchio MP, Parolaro D (2004) Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines. J Pharmacol Exp Ther 308: 838–845CrossRefPubMedGoogle Scholar
  77. 77.
    Gallily R, Even-Chena T, Katzavian G, Lehmann D, Dagan A, Mechoulam R (2003) Gamma-irradiation enhances apoptosis induced by cannabidiol, a non-psychotropic cannabinoid, in cultured HL-60 myeloblastic leukemia cells. Leuk Lymphoma 44: 1767–1773CrossRefPubMedGoogle Scholar
  78. 78.
    Baek SH, Kim YO, Kwag JS, Choi KE, Jung WY, Han DS (1998) Boron trifluoride etherate on silica-A modified Lewis acid reagent (VII). Antitumor activity of cannabigerol against human oral epitheloid carcinoma cells. Arch Pharmacol Res 21: 353–356Google Scholar
  79. 79.
    Recht LD, Salmonsen R, Rosetti R, Jang T, Pipia G, Kubiatowski T, Karim P, Ross AH, Zurier R, Litofsky NS, Burstein S (2001) Antitumor effects of ajulemic acid (CT3), a synthetic non-psychoactive cannabinoid. Biochem Pharmacol 62: 755–763CrossRefPubMedGoogle Scholar
  80. 80.
    Bidinger B, Torres R, Rossetti RG, Brown L, Beltre R, Burstein S, Lian JB, Stein GS, Zurier RB (2003) Ajulemic acid, a nonpsychoactive cannabinoid acid, induces apoptosis in human T lymphocytes. Clin Immunol 108: 95–102CrossRefPubMedGoogle Scholar
  81. 81.
    Guzman M, Galve-Roperh I, Sanchez C (2001) Ceramide: a new second messenger of cannabinoid action. Trends Pharmacol Sci 22: 19–22CrossRefPubMedGoogle Scholar
  82. 82.
    Gomez Del Pulgar T, De Ceballos ML, Guzman M, Velasco G (2002) Cannabinoids protect astrocytes from ceramide-induced apoptosis through the phosphatidylinositol 3-kinase/protein kinase B pathway. J Biol Chem 277: 36527–36533CrossRefPubMedGoogle Scholar
  83. 83.
    Molina-Holgado E, Vela JM, Arevalo-Martin A, Almazan G, Molina-Holgado F, Borrell J, Guaza C (2002) Cannabinoids promote oligodendrocyte progenitor survival: involvement of cannabinoid receptors and phosphatidylinositol-3 kinase/Akt signaling. J Neurosci 22: 9742–9753PubMedGoogle Scholar
  84. 84.
    van der Stelt M, Veldhuis WB, Maccarrone M, Bar PR, Nicolay K, Veldink GA, Di Marzo V, Vliegenthart JF (2002) Acute neuronal injury, excitotoxicity, and the endocannabinoid system. Mol Neurobiol 26: 317–346CrossRefPubMedGoogle Scholar
  85. 85.
    Grotenhermen F (2003) Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 42: 327–360PubMedGoogle Scholar
  86. 86.
    Malan TP Jr, Ibrahim MM, Lai J, Vanderah TW, Makriyannis A, Porreca F (2003) CB2 cannabinoid receptor agonists: pain relief without psychoactive effects? Curr Opin Pharmacol 3: 62–67CrossRefPubMedGoogle Scholar
  87. 87.
    Bifulco M, Di Marzo V (2002) Targeting the endocannabinoid system in cancer therapy: a call for further research. Nat Med 8: 547–550CrossRefPubMedGoogle Scholar
  88. 88.
    Tashkin DP, Baldwin GC, Sarafian T, Dubinett S, Roth MD (2002) Respiratory and immunologic consequences of marijuana smoking. J Clin Pharmacol 42: 71S–81SPubMedGoogle Scholar
  89. 89.
    (2003) Cannabis-based medicines—GW pharmaceuticals: high CBD, high THC, medicinal cannabis—GW pharmaceuticals, THC:CBD. Drugs R D 4: 306–309Google Scholar
  90. 90.
    Pertwee RG, Gibson TM, Stevenson LA, Ross RA, Banner WK, Saha B, Razdan RK, Martin BR (2000) O-1057, a potent water-soluble cannabinoid receptor agonist with antinociceptive properties. Br JPharmacol 129: 1577–1584CrossRefGoogle Scholar
  91. 91.
    Pertwee RG (2000) Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development. Expert Opin Invest Drugs 9: 1553–1571CrossRefGoogle Scholar
  92. 92.
    Di Carlo G, Izzo AA (2003) Cannabinoids for gastrointestinal diseases: potential therapeutic applications. Expert Opin Invest Drugs 12: 39–49CrossRefGoogle Scholar
  93. 93.
    Tramer MR, Carroll D, Campbell FA, Reynolds DJ, Moore RA, McQuay HJ (2001) Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. Br Med J 323: 16–21Google Scholar
  94. 94.
    Walsh 2003 and James JS (2000) Marijuana safety study completed: weight gain, no safety problems. AIDS Treat News 348: 3–4PubMedGoogle Scholar
  95. 95.
    Barann M, Molderings G, Bruss M, Bonisch H, Urban BW, Gothert M (2002) Direct inhibition by cannabinoids of human 5-HT3A receptors: probable involvement of an allosteric modulatory site. Br J Pharmacol 137: 589–596CrossRefPubMedGoogle Scholar
  96. 96.
    Van Sickle MD, Oland LD, Mackie K, Davison JS, Sharkey KA (2003) Delta9-tetrahydrocannabinol selectively acts on CB 1 receptors in specific regions of dorsal vagal complex to inhibit emesis in ferrets. Am J Physiol Gastrointest Liver Physiol 285: G566–G576PubMedGoogle Scholar
  97. 97.
    Darmani NA (2001) Delta-9-tetrahydrocannabinol differentially suppresses cisplatin-induced emesis and indices of motor function via cannabinoid CB(1) receptors in the least shrew. Pharmacol Biochem Behav 69: 239–249CrossRefPubMedGoogle Scholar
  98. 98.
    Darmani NA, Johnson JC (2004) Central and peripheral mechanisms contribute to the antiemetic actions of delta-9-tetrahydrocannabinol against 5-hydroxytryptophan-induced emesis. Eur J Pharmacol 488: 201–212CrossRefPubMedGoogle Scholar
  99. 99.
    Darmani NA, Janoyan JJ, Kumar N, Crim JL (2003) Behaviorally active doses of the CB1 receptor antagonist SR 141716A increase brain serotonin and dopamine levels and turnover. Pharmacol Biochem Behav 75: 777–787CrossRefPubMedGoogle Scholar
  100. 100.
    Yamakuni H, Sawai-Nakayama H, Imazumi K, Maeda Y, Matsuo M, Manda T, Mutoh S (2002) Resiniferatoxin antagonizes cisplatin-induced emesis in dogs and ferrets. Eur J Pharmacol 442: 273–278CrossRefPubMedGoogle Scholar
  101. 101.
    Kirkham TC, Williams CM, Fezza F, Di Marzo V (2002) Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol 136: 550–557CrossRefPubMedGoogle Scholar
  102. 102.
    Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, Jarai Z, Fezza F, Miura GI, Palmiter RD, Sugiura T, Kunos G (2001) Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410: 822–825CrossRefPubMedGoogle Scholar
  103. 103.
    Cota D, Marsicano G, Tschop M, Grubler Y, Flachskamm C, Schubert M, Auer D, Yassouridis A, Thone-Reineke C, Ortmann S et al. (2003) The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 112: 423–431CrossRefPubMedGoogle Scholar
  104. 104.
    Jatoi A, Windschitl HE, Loprinzi CL, Sloan JA, Dakhil SR, Mailliard JA, Pundaleeka S, Kardinal CG, Fitch TR, Krook JE et al. (2002) Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol 20: 567–573CrossRefPubMedGoogle Scholar
  105. 105.
    Iversen L, Chapman V (2002) Cannabinoids: a real prospect for pain relief? Curr Opin Pharmacol 2: 50–55CrossRefPubMedGoogle Scholar
  106. 106.
    Walker JM, Huang SM, Strangman NM, Tsou K, Sanudo-Pena MC (1999) Pain modulation by release of the endogenous cannabinoid anandamide. Proc Natl Acad Sci USA 96: 12198–12203CrossRefPubMedGoogle Scholar
  107. 107.
    Pertwee RG (2001) Cannabinoid receptors and pain. Prog Neurobiol 63: 569–611CrossRefPubMedGoogle Scholar
  108. 108.
    Mantyh PW, Clohisy DR, Koltzenburg M, Hunt SP (2002) Molecular mechanisms of cancer pain. Nat Rev Cancer 2: 201–209CrossRefPubMedGoogle Scholar
  109. 109.
    Campbell FA, Tramer MR, Carroll D, Reynolds DJ, Moore RA, McQuay HJ (2001) Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. Br Med J 323: 13–16Google Scholar
  110. 110.
    Naef M, Curatolo M, Petersen-Felix S, Arendt-Nielsen L, Zbinden A, Brenneisen R (2003) The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions. Pain 105: 79–88CrossRefPubMedGoogle Scholar
  111. 111.
    Cichewicz DL (2004) Synergistic interactions between cannabinoid and opioid analgesics. Life Sci 74: 1317–1324CrossRefPubMedGoogle Scholar
  112. 112.
    Haller J, Bakos N, Szirmay M, Ledent C, Freund TF (2002) The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. Eur J Neurosci 16: 1395–1398CrossRefPubMedGoogle Scholar
  113. 113.
    Kathuria S, Gaetani S, Fegley D, Valino F, Duranti A, Tontini A, Mor M, Tarzia G, La Rana G, Calignano A et al. (2003) Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9: 76–81CrossRefPubMedGoogle Scholar
  114. 114.
    Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, Hermann H, Tang J, Hofmann C, Zieglgansberger W et al. (2002) The endogenous cannabinoid system controls extinction of aversive memories. Nature 418: 530–534CrossRefPubMedGoogle Scholar
  115. 115.
    Bisogno T, Melck D, Bobrov MYu, Gretskaya NM, Bezuglov VV, De Petrocellis L, Di Marzo V (2000) N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem J 351: 817–824CrossRefPubMedGoogle Scholar
  116. 116.
    Jones S, Howl J (2003) Cannabinoid receptor systems: therapeutic targets for tumour intervention. Expert Opin Ther Targets 7: 749–758CrossRefPubMedGoogle Scholar
  117. 117.
    Bifulco M, Laezza C, Valenti M, Ligresti A, Portella G, Di Marzo V (2004) A new strategy to block tumor growth by inhibiting endocannabinoid inactivation. FASEB J 18: 1606–1608PubMedGoogle Scholar
  118. 118.
    Contassot E, Wilmotte R, Tenan M, Belkouch MC, Schnuriger V, de Tribolet N, Burkhardt K, Dietrich PY (2004) Arachidonylethanolamide induces apoptosis of human glioma cells through vanilloid receptor-1. JNeuropathol Exp Neurol 63: 956–963Google Scholar
  119. 119.
    Blazquez C, Gonzalez-Feria L, Alvarez L, Haro A, Casanova ML, Guzman M. (2004) Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. Cancer Res 64: 5617–5623PubMedGoogle Scholar
  120. 120.
    Nithipatikom K, Endsley MP, Isbell MA, Falck JR, Iwamoto Y, Hillard CJ, Campbell WB (2004) 2-arachidonoylglycerol: a novel inhibitor of androgen-independent prostate cancer cell invasion. Cancer Res 64: 8826–8830PubMedGoogle Scholar

Copyright information

© Birkhäuser Verlag/Switzerland 2005

Authors and Affiliations

  • Luciano De Petrocellis
    • 1
  • Maurizio Bifulco
    • 2
  • Alessia Ligresti
    • 3
  • Vincenzo Di Marzo
    • 3
  1. 1.Consiglio Nazionale delle RicercheIstituto di Cibernetica “Eduardo Caianiello”Pozzuoli (Napoli)Italy
  2. 2.Istituto di Endocrinologia ed Oncologia Sperimentale, Consiglio Nazionale delle Ricerche, and Dipartimento di Scienze FarmaceuticheUniversità degli Studi di SalernoFisciano (SA)Italy
  3. 3.Consiglio Nazionale delle RicercheIstituto di Chimica BiomolecolarePozzuoli (Napoli)Italy

Personalised recommendations